China Pharma Holding (STU:XQJ0) ROCE % : -36.42% (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is China Pharma Holding ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China Pharma Holding's annualized ROCE % for the quarter that ended in Mar. 2024 was -36.42%.

China Pharma Holding ROCE % Historical Data

The historical data trend for China Pharma Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding ROCE % Chart

China Pharma Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-87.30

-22.31

-27.00

-43.09

-36.99

China Pharma Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-30.17	-34.16	-42.52	-52.18	-36.42

China Pharma Holding ROCE % Calculation

China Pharma Holding's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2.517	/	( ( (16.788 - 12.026)	+	(15.102 - 6.255) )	/ 2 )
	=	-2.517	/	( (4.762	+	8.847)	/ 2 )
	=	-2.517	/	6.8045
	=	-36.99 %

China Pharma Holding's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-3.364	/	( ( (15.102 - 6.255)	+	(14.895 - 5.27) )	/ 2 )
	=	-3.364	/	( ( 8.847	+	9.625 )	/ 2 )
	=	-3.364	/	9.236
	=	-36.42 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

China Pharma Holding (STU:XQJ0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

China Pharma Holding ROCE % Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

China Pharma Holding (STU:XQJ0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (STU:XQJ0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CPHI:USA

Address

Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216

Website

https://www.chinapharmaholdings.com

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

China Pharma Holding (STU:XQJ0) Headlines

No Headlines